Megan E Mcnerney

List of Publications by Year
in descending order

37 papers	1,729 citations	471509 17 h-index	414414 32 g-index
37 all docs	37 docs citations	37 times ranked	3165 citing authors

#	Article	IF	Citations
1	Genomic studies controvert the existence of the CUX1 p75 isoform. Scientific Reports, 2022, 12, 151.	3.3	1
2	CRISPR screening in human hematopoietic stem and progenitor cells reveals an enrichment for tumor suppressor genes within chromosome 7 commonly deleted regions. Leukemia, 2022, 36, 1421-1425.	7.2	3
3	The significance of CUX1 and chromosome 7 in myeloid malignancies. Current Opinion in Hematology, 2022, 29, 92-102.	2.5	6
4	Loss of a 7q gene,CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms. Blood, 2021, 138, 790-805.	1.4	13
5	Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells. Cell Death and Disease, 2021, 12, 1005.	6.3	8
6	CUX1 Deficiency Potentiates RAS Signaling to Drive Malignancy. Blood, 2021, 138, 1159-1159.	1.4	0
7	Cytotoxic Therapyâ€“Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid Neoplasms. Blood Cancer Discovery, 2020, 1, 32-47.	5.0	16
8	A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Advances, 2020, 4, 599-606.	5.2	9
9	Deficiency of CUX1, Encoded on 7q, Blocks the Normal HSC DNA Damage Response and Drives Highly Penetrant Therapy-Related Myeloid Neoplasms in Mice. Blood, 2019, 134, 641-641.	1.4	5
10	System for Informatics in the Molecular Pathology Laboratory. Journal of Molecular Diagnostics, 2018, 20, 522-532.	2.8	8
11	Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood, 2018, 131, 2682-2697.	1.4	36
12	The Harmful Consequences of Increased Fitness in Hematopoietic Stem Cells. Cell Stem Cell, 2018, 23, 634-635.	11.1	4
13	The haploinsufficient tumor suppressor, CUX1, acts as an analog transcriptional regulator that controls target genes through distal enhancers that loop to target promoters. Nucleic Acids Research, 2017, 45, 6350-6361.	14.5	21
14	Therapy-related myeloid neoplasms: when genetics and environment collide. Nature Reviews Cancer, 2017, 17, 513-527.	28.4	270
15	Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. Journal of Molecular Diagnostics, 2017, 19, 43-56.	2.8	105
16	Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression. PLoS Genetics, 2017, 13, e1006589.	3.5	53
17	Deficiency of Cux1, Encoded on Human Chromosome 7q, Causes Aberrant Hematopoietic Stem Cell Function and Spontaneous Myeloproliferative Disease in Mice. Blood, 2017, 130, 789-789.	1.4	10
18	Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms. Haematologica, 2016, 101, e232-e236.	3.5	13

#	Article	IF	Citations
19	Enhancer-Promoter Looping Deciphers Dosage of the Haploinsufficient Transcription Factor, CUX1. Blood, 2016, 128, 2700-2700.	1.4	0
20	Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nature Genetics, 2015, 47, 539-543.	21.4	39
21	Bionimbus: a cloud for managing, analyzing and sharing large genomics datasets. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 969-975.	4.4	66
22	The spectrum of somatic mutations in highâ€risk acute myeloid leukaemia with â€7/del(7q). British Journal of Haematology, 2014, 166, 550-556.	2.5	29
23	Widespread genetic epistasis among cancer genes. Nature Communications, 2014, 5, 4828.	12.8	63
24	Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in Nras-Driven Hematopoietic Transformation. Cancer Discovery, 2013, 3, 993-1001.	9.4	60
25	CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood, 2013, 121, 975-983.	1.4	130
26	Retroviral Insertional Mutagenesis In Egr1+/- mice, Haploinsufficient For a Human Del(5q) Myeloid Leukemia Gene, Develop Myeloid Neoplasms With Proviral Insertions In Genes Syntenic To Human 5q. Blood, 2013, 122, 1275-1275.	1.4	0
27	An Integrated Genomic Approach to the Assessment and Treatment of Acute Myeloid Leukemia. Seminars in Oncology, 2011, 38, 215-224.	2.2	21
28	Next-Generation Sequencing Analysis of 23 Therapy-Related Acute Myeloid Leukemia Transcriptomes. Blood, 2010, 116, 850-850.	1.4	2
29	Development of warm auto- and allo-antibodies in a 3-year old boy with sickle cell haemoglobinopathy following his first transfusion of a single unit of red blood cells. Blood Transfusion, 2010, 8, 126-8.	0.4	7
30	Natural killer cell subsets in allograft rejection and tolerance. Current Opinion in Organ Transplantation, 2007, 12, 10-16.	1.6	0
31	Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions. Blood, 2006, 107, 3181-3188.	1.4	78
32	2B4 (CD244)-CD48 interactions provide a novel MHC class I-independent system for NK-cell self-tolerance in mice. Blood, 2005, 106, 1337-1340.	1.4	50
33	A new self: MHC-class-I-independent Natural-killer-cell self-tolerance. Nature Reviews Immunology, 2005, 5, 363-374.	22.7	156
34	Targeted Disruption of the2B4Gene in Mice Reveals an In Vivo Role of 2B4 (CD244) in the Rejection of B16 Melanoma Cells. Journal of Immunology, 2005, 174, 800-807.	0.8	88
35	2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells. Molecular Immunology, 2005, 42, 489-494.	2.2	90
36	2B4 Acts As a Nonâ€“Major Histocompatibility Complex Binding Inhibitory Receptor on Mouse Natural Killer Cells. Journal of Experimental Medicine, 2004, 199, 1245-1254.	8.5	179

#	Article	IF	Citations
37	Regulatory Defects in Cbl and Mitogen-Activated Protein Kinase (Extracellular Signal-Related Kinase) Pathways Cause Persistent Hyperexpression of CD40 Ligand in Human Lupus T Cells. Journal of Immunology, 2000, 165, 6627-6634.	0.8	90